ArticleCureus2022

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma.

Sethi Ashish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.